Abstract
Summary
Prophylactic treatment with heterologous anti-PMN leucocyte serum at a leucopenic dose inhibited the intensity of the primary lesion, and delayed but did not prevent the development of the secondary joint lesions. When given therapeutically, anti-PMN leucocyte serum did not reduce the hind leg edema, despite a significant reduction in peripheral blood PMN leucocytes. Cutaneous sensitivity to PPD was unaffected by anti-PMN serum. The data suggest that the PMN leucocytes may play a role in the initiation, but not the maintenace, of adjuvant disease.
Get full access to this article
View all access options for this article.